David Weingarten, PhD, and Mark Feldstein, PhD, will present ways to optimize pharma patent protection to avoid generic competition and increase return on investment at CPhI North America 2018.
Attorneys David Weingarten, PhD, and Mark Feldstein, PhD, will explore ways to optimize pharma patent protection to avoid generic competition and increase return on investment at insight briefing
Weingarten is an associate at Finnegan, Henderson, Farabow, Garratt & Dunner. His practice focuses on patent litigation before United States district courts and the US International Trade Commission, post-grant trial proceedings at the US Patent and Trademark Office (USPTO), prosecution, and strategic portfolio management. His practice includes chemical, pharmaceutical, biotechnology, and consumer-product areas. Prior to practicing law, David spent more than a decade in the pharmaceutical industry developing drugs across a range of therapeutic areas.
Feldstein, PhD, is a partner at Finnegan, Henderson, Farabow, Garratt & Dunner. Feldstein focuses on US district court litigation, primarily concerning the enforcement of US patent rights and trade secret issues, and post-grant trial proceedings at the USPTO, including inter partes review and post grant review. Feldstein’s practice covers a range of technologies, including pharmaceuticals, biochemistry, polymers, small-molecule chemistry, nanotechnology, optics, and medical and analytic devices.
For more information and to
Source:
